{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04189432",
      "OrgStudyIdInfo": {
        "OrgStudyId": "SCM-CGH2001"
      },
      "Organization": {
        "OrgFullName": "SCM Lifescience Co., LTD.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease",
      "OfficialTitle": "A Multicenter, Randomized, Parallel Group, Double-blind, Phase 2 Trial to Evaluate Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "September 28, 2016",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 31, 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 31, 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "December 4, 2019",
      "StudyFirstSubmitQCDate": "December 4, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 6, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "September 26, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 28, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "SCM Lifescience Co., LTD.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate efficacy of SCM-CGH in participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and partial response [PR] defined by National Institutes of Health [NIH] consensus development project criteria [2014])."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Chronic Graft-versus-host-disease"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "A Multicenter, Randomized, Parallel Group, Double-blind",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "77",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "SCM-CGH",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells\nDose: 1x10^6 cells/Kg",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: SCM-CGH"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "3 times with 2-week intervals by IV infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "SCM-CGH",
            "InterventionDescription": "SCM-CGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "SCM-CGH"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Placebo",
            "InterventionDescription": "Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Percentage of Participants who Achieve Complete Response (CR) or Partial Response (PR) (i.e. Overall Response Rate [ORR])",
            "PrimaryOutcomeDescription": "ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR). Response is defined by the National Institutes of Health (NIH) Consensus Development Project Criteria (2014) and must occur, in the absence of new therapy for chronic graft versus host disease (cGVHD) and absence of progression of underlying disease or death. CR: Resolution of all manifestations in each organ or site. PR: Improvement in at least 1 organ or site without progression in any other organ or site. cGVHD Progression: Clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.",
            "PrimaryOutcomeTimeFrame": "Week 12"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Percentage of Participants who Achieve Complete Response (CR) or Partial Response (PR) (i.e. Overall Response Rate [ORR]).",
            "SecondaryOutcomeDescription": "ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR). Response is defined by the National Institutes of Health (NIH) Consensus Development Project Criteria (2014) and must occur, in the absence of new therapy for chronic graft versus host disease (cGVHD) and absence of progression of underlying disease or death. CR: Resolution of all manifestations in each organ or site. PR: Improvement in at least 1 organ or site without progression in any other organ or site. cGVHD Progression: Clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.",
            "SecondaryOutcomeTimeFrame": "Week 0, 2, 4, 6, 8, 16, 20, 24 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Organ-specific Assessments",
            "SecondaryOutcomeDescription": "Percentage of participants with organ-specific assessments is defined as rate of NIH defined CR or PR.",
            "SecondaryOutcomeTimeFrame": "Week 0, 2, 4, 6, 8, 16, 20, 24 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Patient-Reported Outcomes",
            "SecondaryOutcomeDescription": "Patient-reported Chronic GVHD-specific Measures are defined by the National Institutes of Health (NIH) Consensus Development Project Criteria (2014).",
            "SecondaryOutcomeTimeFrame": "Week 0, 2, 4, 6, 8, 16, 20, 24 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Clinician-Assessed Global Rating/Scale",
            "SecondaryOutcomeDescription": "Global Rating(0~3)/Scale(0~10) of clinician-assessed chronic GVHD-specific measures are defined by the National Institutes of Health (NIH) Consensus Development Project Criteria (2014).",
            "SecondaryOutcomeTimeFrame": "Week 0, 2, 4, 6, 8, 16, 20, 24 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Failure-free Survival",
            "SecondaryOutcomeDescription": "Failure-free survival, defined as absence of relapse, death and addition of new treatment, survival free of impairment, or reduction in steroid dosing that do not rely on direct assessment of organ responses.",
            "SecondaryOutcomeTimeFrame": "Week 24 and 48"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSubjects who are males or females aged >= 19 years, 40kg to 80kg in weight\nSteroid dependent/refractory chronic graft versus host disease (cGVHD) defined as the National Institutes of Health (NIH) criteria (2014) below at any time post-hematopoietic cell transplant (post-HCT):\n\nRefractory disease, defined as, 1) when cGVHD manifestations progress despite the use of a regimen containing glucocorticoid (prednisolone at >=1 mg/kg/day for at least 2 weeks) or 2), 3) Persist without improvement despite continued treatment with glucocorticoid (prednisolone at >=0.5 mg/kg/day or 1 mg/kg every other day) for at least 4 weeks Dependent disease, defined as, 4), 5) when glucocorticoid (prednisolone doses greater than or equal to [>=] 0.25 milligram per kilogram per day (mg/kg/day)or >=0.5 milligram per kilogram (mg/kg) every other day) are needed to prevent recurrence or progression of manifestations as demonstrated by unsuccessful attempts to taper the dose to lower levels on at least 2 occasions, separated by at least 8 weeks.\n\nParticipants must be receiving less than 3 systemic glucocorticoid therapies or other immunosuppressive therapies in addition to glucocorticoids for cGVHD for at least 4 weeks before Screening visit. The dose of steroids or Immunosuppressant must be stable for 14 days(2 weeks) prior to starting SCM-CGH or Placebo.\nLaboratory test sufficiency as follows; Absolute neutrophil count (ANC) â‰¥ 1,000 cells/mm3 Serum creatinine < 2 x upper limit of normal (ULN)\n\nExclusion Criteria:\n\nActive acute graft versus host disease (GVHD)\nActive infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus (HCV)\nUncontrolled underlying disease such as moderate or severe infections and hemorrhage\nSevere Heart failure (NYHA class III/IV), congestive heart failure or arrhythmia requiring treatment\nHistory of allogenic hematopoietic stem cell more than once\nPositive reaction of a Penicillin test at screening\nHistory of relapse of causative diseases (ALL, CML, CLL, AML, NHL, multiple myeloma e.t.c.) with hematopoietic stem cell transplantation or diagnosed with secondary malignant diseases after hematopoietic stem cell transplantation\nHistory of Anti-thymocyte globulin(ATG) for 2 weeks before Screening visit\nHistory of pulmonary embolism or deep venous thrombosis for 24 weeks before Screening visit",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "19 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Bawi Kim",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+82-2-6001-3542",
            "CentralContactEMail": "bwkim@scmlifescience.com"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "National Cancer Center",
            "LocationStatus": "Recruiting",
            "LocationCity": "Goyang-si",
            "LocationState": "Gyeonggi-do",
            "LocationZip": "10408",
            "LocationCountry": "Korea, Republic of",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Eunyoung Lee",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+82-31-920-1682",
                  "LocationContactEMail": "eunyounglee@ncc.re.kr"
                }
              ]
            }
          },
          {
            "LocationFacility": "Inha University Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Incheon",
            "LocationZip": "22332",
            "LocationCountry": "Korea, Republic of",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Jin Hyun Cho",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+82-32-890-2581",
                  "LocationContactEMail": "henkengun@gmail.com"
                }
              ]
            }
          },
          {
            "LocationFacility": "Seoul National University Seoul",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seoul",
            "LocationZip": "03080",
            "LocationCountry": "Korea, Republic of",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Inho Kim",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+82-2-2072-0834",
                  "LocationContactEMail": "ihkimmd@snu.ac.kr"
                }
              ]
            }
          },
          {
            "LocationFacility": "Severance Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seoul",
            "LocationZip": "03722",
            "LocationCountry": "Korea, Republic of",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "JunWon Jung",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+82-2-2228-1970",
                  "LocationContactEMail": "jwcheong70@yuhs.ac"
                }
              ]
            }
          },
          {
            "LocationFacility": "Asan Medical Center",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seoul",
            "LocationZip": "05505",
            "LocationCountry": "Korea, Republic of",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Je-hwan Lee",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+82-2-3010-3218",
                  "LocationContactEMail": "jhlee3@amc.seoul.kr"
                }
              ]
            }
          },
          {
            "LocationFacility": "Samsung Medical Center",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seoul",
            "LocationZip": "06351",
            "LocationCountry": "Korea, Republic of",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Chul Won Jung",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+82-2-3410-3452",
                  "LocationContactEMail": "leukemia2@gmail.com"
                }
              ]
            }
          },
          {
            "LocationFacility": "The Catholic University of Korea Seoul St. Mary's Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seoul",
            "LocationZip": "06591",
            "LocationCountry": "Korea, Republic of",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Yoo-Jin Kim",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+82-2-2258-6057",
                  "LocationContactEMail": "yoojink@catholic.ac.kr"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006086",
            "ConditionMeshTerm": "Graft vs Host Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8341",
            "ConditionBrowseLeafName": "Graft vs Host Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2832",
            "ConditionBrowseLeafName": "Homologous Wasting Disease",
            "ConditionBrowseLeafAsFound": "Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T1303",
            "ConditionBrowseLeafName": "Chronic Graft Versus Host Disease",
            "ConditionBrowseLeafAsFound": "Chronic Graft Versus Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}